NHS Digital has published emergency readmissions statistics for first time in five years.
News
EU gives Uni of St Andrews 4.37m Euros for medical data study
The European Union has announced it is to give The University of St Andrews 4.37 million Euros for a medical data study.
Pfizer buys stake in French gene therapy company Vivet
Pfizer has announced a collaboration with Vivet on the development of a potential breakthrough therapy for Wilson disease.
Biotech growth in UK booms 65% since 2016
The number of active UK biotechnology businesses in the R&D field has soared by 65% in just over three years.
International recruitment needed to fix NHS staff shortages says new report
The King’s Fund think-tank has claimed that in the next five years nurse shortages will double and GP gaps could potentially nearly triple to 7,000.
Genomics plc develops predictive tests for common diseases
Genomics plc has announced the development of predictive genomic tests for 16 common diseases.
Roche bags small cell lung cancer nod for Tecentriq
Roche’s Tecentriq has won US clearance for use in combination with carboplatin and etoposide (chemotherapy) as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) in the US, offering patients the first new treatment in more than 20 years.
Merck, Pfizer pull the plug on ovarian cancer trial
Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in the front-line maintenance setting for ovarian cancer.
US approves first treatment for post-partum depression
Sage Therapeutics’ Zulresso has become first treatment to be approved for post-partum depression in the US.
GSK’s endometrial cancer drug to be filed later this year
GlaxoSmithKline group Tesaro has presented mid-stage data indicating “robust activity” of its anti-PD-1 therapy dostarlimab in patients with advanced or recurrent endometrial cancer, with a filing now on the cards for later this year.
The 2019 PharmaTimes Communications Team of the Year competition is now open for entry!
Unique in the industry, the PharmaTimes Communications Team of the Year competition gives communications professionals the opportunity to demonstrate their skills in a live environment, developing a strategic and tactical programme in response to a fictional, but realistic challenge.
FDA places partial hold on clinical trials of venetoclax for multiple myeloma
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
Scientists develop osteoarthritis pain vaccine
Scientists have developed and tested a vaccine that they say could be used to treat chronic pain caused by osteoarthritis.
AZ’ Farxiga shows CV benefit in diabetes patients
New analysis of trial data highlight cardiovascular benefits of AstraZeneca’s diabetes drug Farxiga.
GW sells priority review voucher for $105m
GW Pharmaceuticals is selling its rare paediatric disease priority review voucher (PRV) for $105 million to Biohaven Pharmaceutical.
